NASDAQ:VLRX - Valeritas Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.29 -0.01 (-3.37 %) (As of 04/22/2019 04:00 PM ET)Previous Close$0.3020Today's Range$0.2820 - $0.302052-Week Range$0.28 - $4.44Volume675,817 shsAverage Volume1.52 million shsMarket Capitalization$29.54 millionP/E RatioN/ADividend YieldN/ABeta2.04 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery. In addition, its products include V-Go Prefill, which is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go Link that is in the early stages of development for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors in the United States. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey. Receive VLRX News and Ratings via Email Sign-up to receive the latest news and ratings for VLRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VLRX Previous Symbol CUSIPN/A CIK1619250 Webwww.valeritas.com Phone908-927-9920Debt Debt-to-Equity Ratio2.82 Current Ratio4.47 Quick Ratio3.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$26.40 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book2.05Profitability EPS (Most Recent Fiscal Year)($1.71) Net Income$-45,930,000.00 Net Margins-173.99% Return on EquityN/A Return on Assets-92.10%Miscellaneous EmployeesN/A Outstanding Shares102,893,000Market Cap$29.54 million Next Earnings Date5/8/2019 (Estimated) OptionableNot Optionable Valeritas (NASDAQ:VLRX) Frequently Asked Questions What is Valeritas' stock symbol? Valeritas trades on the NASDAQ under the ticker symbol "VLRX." How were Valeritas' earnings last quarter? Valeritas Holdings Inc (NASDAQ:VLRX) posted its earnings results on Tuesday, March, 5th. The company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.07. The business had revenue of $6.89 million for the quarter, compared to the consensus estimate of $6.70 million. View Valeritas' Earnings History. When is Valeritas' next earnings date? Valeritas is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Valeritas. What guidance has Valeritas issued on next quarter's earnings? Valeritas issued an update on its first quarter 2019 earnings guidance on Tuesday, March, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $6.2-6.3 million, compared to the consensus revenue estimate of $7.5 million.Valeritas also updated its FY 2019 guidance to EPS. What price target have analysts set for VLRX? 3 brokerages have issued 1 year price objectives for Valeritas' stock. Their predictions range from $1.00 to $3.50. On average, they anticipate Valeritas' stock price to reach $2.1667 in the next year. This suggests a possible upside of 654.7% from the stock's current price. View Analyst Price Targets for Valeritas. What is the consensus analysts' recommendation for Valeritas? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeritas in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Valeritas. Has Valeritas been receiving favorable news coverage? Media stories about VLRX stock have been trending somewhat positive recently, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Valeritas earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the next few days. Who are some of Valeritas' key competitors? Some companies that are related to Valeritas include T2 Biosystems (TTOO), Sensus Healthcare (SRTS), STRATA Skin Sciences (SSKN), Motus GI (MOTS), iCAD (ICAD), Apollo Endosurgery (APEN), CAS Medical Systems (CASM), Spectral Medical (EDTXF), Pro-Dex (PDEX), Repro-Med Systems (REPR), Endologix (ELGX), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Titan Medical (TMDI) and RA Medical Systems (RMED). What other stocks do shareholders of Valeritas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Valeritas investors own include General Electric (GE), Mattel (MAT), Ultra Clean (UCTT), Twitter (TWTR), US Foods (USFD), American National BankShares (AMNB), Enterprise Bancorp (EBTC), Alibaba Group (BABA), General Motors (GM) and New York Times (NYT). Who are Valeritas' key executives? Valeritas' management team includes the folowing people: Mr. John E. Timberlake, Pres, CEO & Director (Age 54)Mr. Erick J. Lucera CPA, CFA, Chief Financial Officer (Age 51)Mr. Geoffrey H. Jenkins, Exec. VP of Manufacturing, Operations and R&D (Age 67)Dr. Matthew H. Nguyen, Chief Commercial Officer (Age 49)Mr. Scott A. Huie, VP of Regulatory Affairs/Quality Assurance and Compliance When did Valeritas IPO? (VLRX) raised $60 million in an initial public offering on Thursday, March 23rd 2017. The company issued 6,000,000 shares at a price of $9.00-$11.00 per share. Cowen and Company and Wedbush PacGrow acted as the underwriters for the IPO and Roth Capital Partners and B. Riley & Co. were co-managers. Who are Valeritas' major shareholders? Valeritas' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (1.44%). Company insiders that own Valeritas stock include Armistice Capital Master Fund, Erick Lucera, John Edward Timberlake, Joseph M Mandato, Matt Nguyen, Matt Nguygn and Peter Devlin. View Institutional Ownership Trends for Valeritas. Which major investors are selling Valeritas stock? VLRX stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View Insider Buying and Selling for Valeritas. How do I buy shares of Valeritas? Shares of VLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Valeritas' stock price today? One share of VLRX stock can currently be purchased for approximately $0.2871. How big of a company is Valeritas? Valeritas has a market capitalization of $29.54 million and generates $26.40 million in revenue each year. The company earns $-45,930,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. What is Valeritas' official website? The official website for Valeritas is http://www.valeritas.com. How can I contact Valeritas? Valeritas' mailing address is 750 ROUTE 202 SOUTH SUITE 600, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-927-9920 or via email at [email protected] MarketBeat Community Rating for Valeritas (NASDAQ VLRX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 184 (Vote Outperform)Underperform Votes: 101 (Vote Underperform)Total Votes: 285MarketBeat's community ratings are surveys of what our community members think about Valeritas and other stocks. Vote "Outperform" if you believe VLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VLRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/22/2019 by MarketBeat.com StaffFeatured Article: What is Considered a Good Return on Equity (ROE)?